This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

FUREN Group PharmaceuticalLtd マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	12.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

FUREN Group PharmaceuticalLtd CEOがいない、あるいは彼らに関するデータがない。

取締役

名称	ポジション	在職期間	報酬	所有権
Cheng Gong Zhu	Vice Chairman & Board Secretary	12.1yrs	データなし	データなし
Wen Liang Zhu	Deputy GM & Director	14.8yrs	データなし	データなし
Wenyu Zhu	Chairman of the Board of Supervisors	12.1yrs	データなし	データなし
Hui An	Supervisor	12.1yrs	データなし	データなし
Zhihua Jiang	Chairman	3yrs	データなし	データなし
Weidong Chen	Independent Director	3yrs	データなし	データなし
Qinggong Yan	Independent Director	3yrs	データなし	データなし

12.1yrs

平均在職期間

52yo

平均年齢

経験豊富なボード: 600781の取締役会は経験豊富で経験豊富です ( 12.1年の平均在任期間)。

This company listing is no longer active

FUREN Group PharmaceuticalLtd マネジメント

マネジメント基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Less than half of directors are independent

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.38 loss in 3Q 2021)

Now 20% undervalued

Now 21% undervalued

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.38 loss per share (vs CN¥0.04 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.42 loss per share (vs CN¥0.071 profit in 2Q 2020)

Full year 2020 earnings released: CN¥2.06 loss per share (vs CN¥0.74 profit in FY 2019)

New 90-day low: CN¥2.90

New 90-day low: CN¥3.33

New 90-day low: CN¥3.75

Third quarter earnings released

FUREN Group Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

First half earnings released

FUREN Group Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

New 90-day low - CN¥3.69

CEO（最高経営責任者

取締役

平均在職期間

平均年齢

This company listing is no longer active

FUREN Group PharmaceuticalLtd マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Less than half of directors are independent

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.38 loss in 3Q 2021)

Now 20% undervalued

Now 21% undervalued

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2021 earnings released: CN¥0.38 loss per share (vs CN¥0.04 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.42 loss per share (vs CN¥0.071 profit in 2Q 2020)

Full year 2020 earnings released: CN¥2.06 loss per share (vs CN¥0.74 profit in FY 2019)

New 90-day low: CN¥2.90

New 90-day low: CN¥3.33

New 90-day low: CN¥3.75

Third quarter earnings released

FUREN Group Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

First half earnings released

FUREN Group Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

New 90-day low - CN¥3.69

CEO（最高経営責任者

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14